Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06298981 · ClinicalTrials.gov registry record
Pulse Rate and Breathing Rate Accuracy
A clinical trial of Pulse Rate and Breathing Rate, sponsored by Nuralogix Corporation.
- Recruiting
- Registry status
- 60
- Enrollment target
- 1
- Study location
NCT06298981: Recruiting study of Pulse Rate and Breathing Rate, sponsored by Nuralogix Corporation.
NCT06298981 is a study of Pulse Rate and Breathing Rate that is actively recruiting participants, run by Nuralogix Corporation. The registered enrollment target is 60 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06298981, a study of Pulse Rate and Breathing Rate, is actively recruiting participants, sponsored by Nuralogix Corporation.
- RECRUITING
- Registry status
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to conduct a Breathing Rate and Pulse Rate accuracy validation comparing the NuraLogix AMC-SDK to the Reference devices, an FDA cleared End Tidal Carbon Dioxide monitor (GE Datex-Ohmeda) and a standard ECG (GE Datex-Ohmeda) derived heart rate reference. This will be done by manually scoring the collected waveform for data analysis.
Conditions Studied
Interventions
- DEVICE noninvasive and investigational NuraLogix AMC-SDK
Study Locations (1)
Colorado
- Element Materials Technology - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-02-12 |
| Est. Completion | 2024-06-30 |
What NCT06298981 shows while recruiting
NCT06298981 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 60 participants, a relatively small participant target.
The record links to 1 condition, with Pulse Rate and Breathing Rate appearing as the primary indexed condition, and to 1 intervention - of which noninvasive and investigational NuraLogix AMC-SDK is the first listed.
NCT06298981 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT06298981 about?
NCT06298981 is a clinical study titled "Pulse Rate and Breathing Rate Accuracy". The purpose of this study is to conduct a Breathing Rate and Pulse Rate accuracy validation comparing the NuraLogix AMC-SDK to the Reference devices, an FDA cleared End Tidal Carbon Dioxide monitor (GE Datex-Ohmeda) and a standard ECG (GE Datex-Ohmeda) derived heart rate reference. This will be done...
What is the current status of trial NCT06298981?
This trial is currently recruiting. The enrollment target is 60 participants. The study started on 2024-02-12. Estimated completion is 2024-06-30.
What conditions does trial NCT06298981 study?
This clinical trial studies the following conditions: Pulse Rate and Breathing Rate.
What interventions are being tested in trial NCT06298981?
The interventions under investigation include: noninvasive and investigational NuraLogix AMC-SDK (DEVICE).
Who is sponsoring clinical trial NCT06298981?
This trial is sponsored by Nuralogix Corporation, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06298981 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI